Latest from the Blog

1. May 7, 2021

   Innovating Brain Tumor Clinical Trials: Lessons Learned During the COVID-19 Experience

   

   The global COVID-19 pandemic disrupted nearly every facet of life in 2020, and brain cancer research, particularly clinical trials, was not spared from its impacts. As is often the case, though, with disruption comes the opportunity to innovate. Convening key stakeholders across the brain tumor community, the National Brain Tumor Society (NBTS) has taken stock […]

   Read more | 

   Tags: advocacy, brain tumor community, Clinical trials, FDA, NCI, NIH, Patient life, Treatment
2. April 8, 2021

   NBTS Brain Tumor Clinical Trials Report: Q1 2021

   

   It can be hard to keep track of new clinical trial opportunities opening across the United States, especially during the current public health crisis created by the coronavirus (COVID-19). However, there are many clinical trials still actively enrolling patients, and this report provides a summary of the studies that have recently opened or started for […]

   Read more | 

   Tags: astrocytoma, brain cancer, brain tumor, chemotherapy, Clinical trials, DIPG, Ependymoma, GBM, glioblastoma, glioblastoma multiforme, glioma, high-grade glioma, immunotherapy, low-grade glioma, Medulloblastoma, pediatric brain tumor, pediatric cancer, pediatrics, pharmaceutical companies, precision medicine, Treatment
3. April 2, 2021

   Remembering Jeff Kolodin

   

   It is with deep sadness that we share news of the passing of Jeff Kolodin, former chair of the National Brain Tumor Society (NBTS) Board of Directors, due to the effects of COVID. His commitment to the brain tumor community, magnetic personality, and unstoppable perseverance have been an inspiration to patients, caregivers, researchers, corporate partners, […]

   Read more | 

   Tags: Community